Navigation Links
Renal artery stenting falls short in large randomized trial
Date:4/1/2008

CHICAGO, Ill. (April 1, 2008) The largest-ever randomized study to evaluate the effectiveness of catheter-based interventions in patients with narrowing of the renal artery has shown that angioplasty and stenting offer no benefit over medical therapy. Among patients who completed one year of follow-up, there were no differences in the change in kidney function, blood pressure control or the rates of major cardiovascular illness, according to the Angioplasty and Stenting for Renal Artery Lesions (ASTRAL) trial.

The ASTRAL trial is being reported today in a Late-Breaking Clinical Trials session at the SCAI Annual Scientific Sessions in Partnership with ACC i2 Summit (SCAI-ACCi2) in Chicago. SCAI-ACCi2 is a scientific meeting for practicing cardiovascular interventionalists sponsored by the Society for Cardiovascular Angiography and Interventions (SCAI) in partnership with the American College of Cardiology (ACC).

The study also found that 3 percent of patients who underwent renal artery intervention experienced a serious procedural complication, including poorly positioned stents and perforation and dissection of the renal artery.

For 15 years weve had the wherewithal to fix renal artery stenosis and restore patency of the renal artery, said Philip A. Kalra, MD, a consultant nephrologist at Hope Hospital, Salford, and lecturer at the University of Manchester, both in the United Kingdom. Thousands of patients have had this procedure, but no one has ever demonstrated any benefit in randomized control trial testing.

About 7 percent of people over age 65and about 10 percent of people with chronic kidney disease who eventually need dialysishave narrowing, or stenosis, of the renal artery. There are several links between renal artery stenosis and cardiovascular disease. For example, in nine out of 10 cases renal artery stenosis is caused by the build-up of atherosclerotic plaque. Many patients with renal artery stenosis also have coronary and peripheral arterial disease; indeed, these conditions share common risk factors. At least 30 percent of older patients with chronic congestive heart failure have renal artery stenosis. Perhaps most important, uncontrolled high blood pressure often prompts physicians to suspect renal artery stenosisand to treat it with angioplasty and stenting.

To evaluate the clinical effectiveness of renal artery stenting, Dr. Kalra and his colleagues recruited 806 patients with atherosclerotic renal vascular disease (ARVD) from 54 medical centers in the United Kingdom, and four in Australia and New Zealand. Patients had renal failure, with an average serum creatinine of about 2.0 mg/dL. Baseline blood pressure averaged 151/76 mm Hg. More than half were current or ex-smokers, nearly one-third had diabetes and nearly half had coronary artery disease. The degree of renal artery stenosis at baseline was 76 percent, on average.

The researchers randomly assigned patients to catheter-based intervention plus medical therapy or medical therapy alone. Renal artery stenting was successful in widening the renal artery, achieving a residual stenosis of less than 50 percent in 88 percent of patients.

After one year of follow-up, however, there were no differences in the change in serum creatinineit rose by 0.2 mg/dL in both groupsor in rates of renal events, including acute renal failure. Even in the highest-risk patientsthose with a baseline creatinine in the highest third, or who had experienced a rapid deterioration in kidney function in the preceding yearrenal artery angioplasty and stenting offered no significant renal functional benefit at one year, but patient numbers in these sub-groups were fairly small.

Blood pressure fell slowly over time, and by four years, averaged 146/74 mm Hg in both groups. At one year, there was no significant difference in the rates of heart attack, stroke, hospitalization for chest pain or heart failure or the need for coronary intervention or bypass surgery. Risk-adjusted mortality was the same in the two groups.

In this study we were looking at the majority of patients with renal artery stenosisthose in whom there is substantial uncertainty about whether to revascularize, Dr. Kalra said. The message is, you dont put a stent in these patients without more careful evaluation. More often than not, it will make no difference whatsoever in clinical outcomes. However, some patients with renal artery stenosis have more definite indications for revascularization, such as acute renal failure or severe acute heart failure, and they should continue to receive this therapy.

Dr. Kalra will present the results of the "Angioplasty and Stenting for Renal Artery Lesions (ASTRAL) study on Tuesday, April 1 at 10:45 a.m. CDT in the Grand Ballroom, S100.


'/>"/>

Contact: Kathy Boyd David
pr@scai.org
717-422-1181
Weber Shandwick Worldwide
Source:Eurekalert

Related medicine news :

1. Renal Assist Device reduces risk of death from acute kidney failure
2. Statement by Robert D. Foreman, President of The Kidney Care Council, Regarding the HHS Report to Congress A Design for a Bundled End Stage Renal Disease Prospective Payment System
3. PLC Systems Files IDE Supplement to Begin Pivotal Study of RenalGuard(TM) and Provides Update on Planned Development Timeline
4. PLC Systems Receives CE Mark Approval for RenalGuard(TM)
5. UT Southwestern: Patients with mild Cushing syndrome may benefit from adrenalectomy
6. Follow-up imaging of benign-appearing incidental adrenal masses is unnecessary
7. Renal Solutions, Inc. Announces Acquisition by Fresenius Medical Care
8. Serum carcinoembryonic antigen level can reflect adrenal adenoma
9. FDA Approves MIRCERA(R): First Renal Anemia Treatment with Monthly Maintenance Dosing
10. PLC Medical Systems to Display RenalGuard(TM) During Renal Week 2007
11. Nephrologists summarize new renal research during public policy news briefing at Renal Week
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... ... , ... In the United States, 20 million women and 10 million men ... feel shame for having struggled with an eating disorder as well as common co-occurring ... in Life After an Eating Disorder” -- to be featured at this year’s iaedp ...
(Date:1/20/2017)... ... ... Aquatics Launches New ADA Portable Motion Trek BP 300 Lift. Built for durability, this pool ... it can be wheeled out of the way and stored when not in use. It ... transformed the feedback from customers into specific enhancements and created a new product that is ...
(Date:1/20/2017)... Texas (PRWEB) , ... January 20, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at ... the bible in homes across the world. Yisrayl says this generation is a time like ... is to turn to the Bible. , Yisrayl says he does not want to sound ...
(Date:1/20/2017)... ... , ... Doctor C LLC, a company based out of Arizona that focuses ... the marketing and distribution of its product, The Right C. , The Right C ... than traditional vitamin C supplements. At the trade show, Doctor C had the opportunity ...
(Date:1/20/2017)... , ... January 20, 2017 , ... Lice Troopers, the ... cases in families with school-aged children since the holiday season. , “It happens ... with their families, sharing hugs and taking photos, which is the head-to-head gateway that ...
Breaking Medicine News(10 mins):
(Date:1/21/2017)... , Jan. 20, 2017  Faruqi & Faruqi, LLP, ... Inc. ("KemPharm" or the "Company") (NASDAQ: KMPH ) ... Company and certain officers and directors and underwriters of the ... seek the role of lead plaintiff. The lawsuit ... District Court for Johnson County on ...
(Date:1/20/2017)... , Jan 20, 2017 Research ... Stability Testing Market Trends, Opportunities, and Future" report to their ... This ... sizing, emerging trends, and technologies, and provides a snapshot of the ... is 2015 and forecasts are provided from 2016 to 2020. The ...
(Date:1/19/2017)... Germany Cataract Surgery Devices ... report, "Germany Cataract Surgery Devices Market Outlook to 2022", ... Devices market. The report provides value, in millions of ... within market segements - Phacoemulsification Equipment and Ophthalmic Viscoelastic ... and distribution shares data for each of these market ...
Breaking Medicine Technology: